As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
|Articles|September 21, 2021
OM Pharma Wins Geneva Economy Award
Advertisement
OM Pharma, a Geneva, Switzerland-based biopharmaceutical company, active in the prevention of recurrent respiratory and urinary tract infections and the treatment of vascular diseases has won the 2021 Geneva Economy Award.
The Geneva Economy and Innovation Awards, created in 2012, aim to honor companies whose reputation and influence convey a positive and dynamic image of Geneva.
The independent jury noted OM Pharma’s economic and social policy. Aiming at the long-term development of the company, all its profits are reinvested in research and development (R&D) and the expansion of its Geneva site.
OM Pharma is a private company founded in Geneva in 1937. The company employs a total of 400 people, including 300 in Geneva and 40 in Fribourg.
Advertisement
Related to this article
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
4
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
5